Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy

Study Aiming to Measure the Impact on Immune Activation and Inflammatory Markers of Switching From a Triple Combination Antiretroviral Therapy (cART) to a Long Acting Dual Therapy in HIV-infected Patients

The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HIV-infected patients

Patients meeting the inclusion criteria will be offered to participate to the study.

In case of acceptance by given their writting consent, 6 ml of blood will be collected for measuring immune activation and inflammatory markers, during the blood test scheduled for the routine follow-up.

Six months after cART change, an equal volume of blood will be collected for measuring the same immune activation and inflammatory markers

Inclusion Criteria:

• Patients agreeing to participate to the study and to collect their data
• HIV-1 infected subjects
• Patients switching from a stable (at least 6 months) and successful triple cART to a long acting dual cART
• Patients older than 18 yrs and regularly followed in Cannes and Nice hospitals
• Patients with a healthcare card

Exclusion Criteria:

• HIV-2 infected subjects
• Patients not being on successful and stable cART
• Patients having being treated during acute HIV-infection
• Patients modifying cART for virological failure
• Subjects modifying their treatment for another combination than from a triple cART to a dual cART
• Patients modifying cART during the 6 months of follow-up
• Patients refusing to participate to the study
• Patients included in an interventional study during the 6 months of follwo-up
• Patient under juridical procedure